Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

This study is comparing two different treatment schedules before surgery in patients with locally advanced esophageal squamous cell carcinoma (a type of throat cancer): 2 cycles versus 4 cycles of the immunotherapy drug adebrelimab combined with chemotherapy, to find out which approach is safer and more effective before tumor removal surgery. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with locally advanced esophageal squamous cell carcinoma confirmed by biopsy - Your cancer is in the chest portion of the esophagus and has not spread to distant organs - You have never received any prior treatment for esophageal cancer (no radiation, chemotherapy, or surgery) - Surgery is planned after completing the treatment, and you are considered a good surgical candidate - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have received any prior treatment for esophageal cancer - Your cancer has spread to distant parts of the body (stage IV) - You have serious organ function problems or blood abnormalities - You have contraindications to surgery - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.